Prognostic significance of vascular invasion and cell-proliferation activity in widely invasive follicular carcinoma of the thyroid.


Journal

Endocrine journal
ISSN: 1348-4540
Titre abrégé: Endocr J
Pays: Japan
ID NLM: 9313485

Informations de publication

Date de publication:
28 Aug 2021
Historique:
pubmed: 23 3 2021
medline: 21 1 2022
entrez: 22 3 2021
Statut: ppublish

Résumé

Widely invasive follicular thyroid carcinoma (wi-FTC) is regarded as having an aggressive character and a dire prognosis, but it has not been known whether all wi-FTCs have a dire prognosis. Herein we retrospectively analyzed the cases of 133 patients with wi-FTCs to determine the prognostic significance of vascular invasion and cell-proliferation activity based on the Ki-67 labeling index (LI). Of the 119 patients without distant metastasis (M0), 11 (9.2%) showed recurrence during the postoperative follow-up. In a univariate analysis, the recurrence-free survival (RFS) rates of the M0 patients with vascular invasion and those with a Ki-67 LI ≥5% were significantly poorer (p = 0.0013 and p = 0.0268, respectively) than those of the patients without vascular invasion or with a Ki-67 LI <5%. Other clinicopathological factors such as patient age, gender, tumor size, and oxyphilic tumor were not significantly related to the patients' RFS. In a multivariate analysis, positive vascular invasion independently affected the RFS (p = 0.0133), but Ki-67 >5% did not (p = 0.1348). To date, only five patients have died of their thyroid carcinoma; four cases were M1. In conclusion, although M0 wi-FTC generally has a favorable prognosis, cases with positive vascular invasion or a high Ki-67 LI are likely to recur, and careful postoperative follow-up is necessary.

Identifiants

pubmed: 33746136
doi: 10.1507/endocrj.EJ21-0064
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

881-888

Auteurs

Yasuhiro Ito (Y)

Department of Surgery, Kuma Hospital, Kobe, Hyogo 650-0011, Japan.

Mitsuhiro Hirokawa (M)

Department of Diagnostic Pathology and Cytology, Kuma Hospital, Kobe, Hyogo 650-0011, Japan.

Makoto Fujishima (M)

Department of Surgery, Kuma Hospital, Kobe, Hyogo 650-0011, Japan.

Hiroo Masuoka (H)

Department of Surgery, Kuma Hospital, Kobe, Hyogo 650-0011, Japan.

Takuya Higashiyama (T)

Department of Surgery, Kuma Hospital, Kobe, Hyogo 650-0011, Japan.

Minoru Kihara (M)

Department of Surgery, Kuma Hospital, Kobe, Hyogo 650-0011, Japan.

Naoyoshi Onoda (N)

Department of Surgery, Kuma Hospital, Kobe, Hyogo 650-0011, Japan.

Akihiro Miya (A)

Department of Surgery, Kuma Hospital, Kobe, Hyogo 650-0011, Japan.

Akira Miyauchi (A)

Department of Surgery, Kuma Hospital, Kobe, Hyogo 650-0011, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH